Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DNLI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsDenali Therapeutics reports Q1 2026 financial results
Filed May 7, 2026 · Period ending May 7, 2026 · ~1 min read
Key Changes
-
medium
Denali announced first quarter 2026 earnings through a press release on May 7, 2026. Actual financial figures are contained in the press release exhibit, not in the 8-K filing body itself.
Item 2.02 verify on EDGAR →
Summary
Denali Therapeutics filed an 8-K to announce its first quarter 2026 financial results on May 7, 2026. This is a routine quarterly earnings disclosure required by SEC regulations. The filing itself serves as a formal notification, with the actual financial data and management commentary contained in the attached press release exhibit. For retail investors, this represents a standard quarterly update.
The key information—revenue, expenses, cash position, and pipeline progress—would be found in the press release and any accompanying earnings call. Investors should review the full press release for specific financial metrics and any updates on Denali's clinical programs. Watch for management's commentary on clinical trial progress and cash runway, as these are critical factors for a clinical-stage biotech company like Denali.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.
The company disclosed its first quarter 2026 financial results through a press release. The 8-K itself does not contain the actual financial figures, which are referenced as being in the attached Exhibit 99.1 press release.
Event · Item 9.01 — Financial Statements and Exhibits
Denali Therapeutics filed an 8-K referencing a press release dated May 7, 2026, with no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release dated May 7, 2026.
The 8-K references a press release dated May 7, 2026 (Exhibit 99.1), but the filing body itself contains no substantive disclosure about the content or nature of the announcement. The actual material information would be in the press release exhibit, which is not included in the provided text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify